Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease - Concepedia

Concepedia

Publication | Open Access

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

DOI Full Paper Access

808

Citations

33

References

2011

Year

Andrew W. Roberts, John F. Seymour, Jennifer R. Brown, William G. Wierda, Thomas J. Kipps, Seong Lin Khaw, Dennis Carney, Simon He, David C.S. Huang, Hao Xiong,

Journal of Clinical Oncology

Abstract

BCL2 is a valid therapeutic target in CLL, and its inhibition by navitoclax warrants further evaluation as monotherapy and in combination in this disease.

References

	Year	Citations

Page 1